What ADPT derivative securities related to this Form 4 are reported for Francis Lo?

The Form 4 reports a stock option (right to buy) with an exercise price of $3.99 per share, of which 3,125 options were exercised on January 2, 2026 , leaving 104,856 derivative securities beneficially owned.

How was the ADPT sale price of $16.08 per share determined in the Form 4?

The Form 4 explains that $16.08 is a weighted-average price for multiple sale transactions, with individual trade prices ranging from $15.77 to $16.40 per share.

Adaptive Biotechnologies (NASDAQ: ADPT) CPO logs 3,125-share option exercise and sale

Q: What insider transactions did ADPT Chief People Officer Francis Lo report?

Francis Lo reported exercising a stock option for 3,125 shares of Adaptive Biotechnologies common stock at $3.99 per share and selling 3,125 shares at a weighted-average price of $16.08 on January 2, 2026 .

Q: How many ADPT shares does Francis Lo own after the reported transactions?

After the transactions, Francis Lo beneficially owned 315,978 shares of Adaptive Biotechnologies common stock directly and 2,500 shares indirectly through spouse You Jin Lee .

Q: What is the vesting schedule for the ADPT stock options reported by Francis Lo?

According to the footnote, the options vested as to 1/4 of the shares on March 4, 2025 , with 1/48 of the shares vesting at the end of each full month of continuous service thereafter until fully vested.

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Adaptive Biotechnologies Corp Chief People Officer Francis Lo reported an option exercise and matching share sale under a pre-set trading plan. On January 2, 2026, Lo exercised a stock option for 3,125 shares of common stock at an exercise price of $3.99 per share and then sold 3,125 shares of common stock at a weighted-average price of $16.08 per share. The filing states these transactions were effected under a Rule 10b5-1 trading plan adopted on September 15, 2025, which is designed to structure trades in advance. After these transactions, Lo beneficially owned 315,978 shares of Adaptive Biotechnologies common stock directly and 2,500 shares indirectly through spouse You Jin Lee, along with 104,856 stock options that remain beneficially owned.

Insider Trade Summary

Net Seller: 3,125 shares ($50,250)

Net Sell 4 txns

Insider LO FRANCIS

Role Chief People Officer

Sold 3,125 shs ($50K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	3,125	$0.00	--
Exercise	Common Stock	3,125	$3.99	$12K
Sale	Common Stock	3,125	$16.08	$50K
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (right to buy) — 104,856 shares (Direct); Common Stock — 319,103 shares (Direct); Common Stock — 2,500 shares (Indirect, By You Jin Lee (spouse))

Footnotes (1)

The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. The price reported for this transaction is a weighted -average price. The shares were sold in multiple transactions ranging from $15.77 to $16.40, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

Form 4 Insider Transactions: What Each Field Means →

01/06/2026 - 07:52 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LO FRANCIS

(Last)

(First)

(Middle)

C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION

1165 EASTLAKE AVE E

(Street)

SEATTLE

98109

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Adaptive Biotechnologies Corp [ ADPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief People Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	01/02/2026		M⁽¹⁾		3,125	A	$3.99	319,103	D
Common Stock	01/02/2026		S⁽¹⁾		3,125	D	$16.08⁽²⁾	315,978	D
Common Stock								2,500	I	By You Jin Lee (spouse)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$3.99	01/02/2026		M⁽¹⁾			3,125	⁽³⁾	03/04/2034	Common Stock	3,125	$0	104,856	D

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.

2. The price reported for this transaction is a weighted -average price. The shares were sold in multiple transactions ranging from $15.77 to $16.40, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

3. The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

	/s/ Francis Lo by Kyle Piskel, Attorney-in-Fact	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did ADPT Chief People Officer Francis Lo report?

Francis Lo reported exercising a stock option for 3,125 shares of Adaptive Biotechnologies common stock at $3.99 per share and selling 3,125 shares at a weighted-average price of $16.08 on January 2, 2026.

Was the ADPT insider trade made under a Rule 10b5-1 plan?

Yes. The filing states the transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by Francis Lo on September 15, 2025.

How many ADPT shares does Francis Lo own after the reported transactions?

After the transactions, Francis Lo beneficially owned 315,978 shares of Adaptive Biotechnologies common stock directly and 2,500 shares indirectly through spouse You Jin Lee.

What is the vesting schedule for the ADPT stock options reported by Francis Lo?

According to the footnote, the options vested as to 1/4 of the shares on March 4, 2025, with 1/48 of the shares vesting at the end of each full month of continuous service thereafter until fully vested.